Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.
about
Matrix Metalloproteinases as Regulators of Vein Structure and Function: Implications in Chronic Venous Disease.Dapper homolog 1 alpha suppresses metastasis ability of gastric cancer through inhibiting planar cell polarity pathway.MiR-130b inhibits proliferation and induces apoptosis of gastric cancer cells via CYLD.Isocitrate dehydrogenase 2 inhibits gastric cancer cell invasion via matrix metalloproteinase 7.YT521 promotes metastases of endometrial cancer by differential splicing of vascular endothelial growth factor A.Impairment of growth of gastric carcinoma by miR-133-mediated Her-2 inhibition.Insulin-like growth factor 1 promotes growth of gastric cancer by inhibiting foxo1 nuclear retention.Vascular endothelial growth factor B coordinates metastasis of non-small cell lung cancer.TGFβ signaling in pancreatic ductal adenocarcinoma.MiR-429 regulates gastric cancer cell invasiveness through ZEB proteins.miR-132 upregulation promotes gastric cancer cell growth through suppression of FoxO1 translation.MiR-153 regulates metastases of gastric cancer through Snail.Fluorouracil induces autophagy-related gastric carcinoma cell death through Beclin-1 upregulation by miR-30 suppression.miR-203 suppression in gastric carcinoma promotes Slug-mediated cancer metastasis.pRb2/p130 localizes to the cytoplasm in diffuse gastric cancer.Matrix Metalloproteinases, Vascular Remodeling, and Vascular Disease.Matrix Metalloproteinases in Remodeling of Lower Extremity Veins and Chronic Venous Disease.Biochemical and Biological Attributes of Matrix Metalloproteinases.Promyelocytic leukemia protein enhances apoptosis of gastric cancer cells through Yes-associated protein.
P2860
Q36316444-D05B271F-C9CF-4B2B-814A-04ED66313A16Q37697176-885CA7AC-67E1-45B0-BE13-4E3A1C9F6F5EQ38808381-804941D1-B3B2-4790-B699-C6FAB46E1C98Q38820611-382FEA8D-C31E-45D4-8055-F68232D58E1CQ38842418-E8D9CAB5-4636-48A8-AEDE-0F3CBD7B28BEQ38863881-55C206B7-D9E5-45C2-9247-9B6F251A51C1Q38919153-F467A64A-27EE-4547-8E19-A7A4665418C9Q38937787-FFA337EC-D088-4E74-A3B0-5A24100A1994Q38943965-42299564-0EFE-4449-A004-5E8AFC27FC8EQ40425587-09D30A15-4955-4288-B972-3E0198E27893Q40616178-EDD9D080-9370-44C6-9BE8-A5E379CD0835Q40670827-67FF31B4-DFE7-42B7-AE00-8EA0833EF44AQ40698326-CA304788-918F-4CC8-B7A4-49627B37E583Q40715074-67E11187-6738-414B-9D8E-02F172A3AADFQ44407120-167C6B8C-406C-44B7-B0A8-E907197F4C5DQ47223491-3A16DD14-4FCA-432F-A8F9-663433C6157AQ51055817-02988D3E-00FA-40E9-BA5D-3BACB6F8B457Q51055833-E6AE0DE7-A8AC-440A-95BB-5E964219986FQ53508674-CD6CDB21-048E-4B78-A075-5BEC15983193
P2860
Molecular basis underlying inhibition of metastasis of gastric cancer by anti-VEGFa treatment.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Molecular basis underlying inh ...... ancer by anti-VEGFa treatment.
@en
type
label
Molecular basis underlying inh ...... ancer by anti-VEGFa treatment.
@en
prefLabel
Molecular basis underlying inh ...... ancer by anti-VEGFa treatment.
@en
P2093
P2860
P1433
P1476
Molecular basis underlying inh ...... ancer by anti-VEGFa treatment.
@en
P2093
P2860
P2888
P304
P356
10.1007/S13277-014-2095-6
P577
2014-05-22T00:00:00Z
P6179
1017071405